Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. After encouraging Phase II trials, Arena is planning Phase IIb/III trials which should provide results a few quarters after ELEVAT-UC colitis studies, by design. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for USD100 per share in an all-cash transaction for a total equity . Get by Email RSS. Potentially a Best-in-Class therapy for pulmonary arterial hypertension (PAH), ralinepag is differentiated from current treatments in that it is a next-generation, oral medication compared to current inhalation therapies. Identify which of Arena Pharmaceuticals Incs products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. Arena Pharmaceuticals Inc Pipeline Drugs - GlobalData GlobalData's premium database helps in identifying which of Arena Pharmaceuticals Inc Pipeline Drugs will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. Even though Orloinab may be just a slice of Arena Pharmas potential revenue, the company has often been included in lists of cannabis drug companies compiled by cannabis industry observers and news outlets. Arena Pharmaceuticalsadd_circleedit_note Submit Changes. Internally, management has stated they are continuing to scale the enterprise with buildout of their commercial and medical affairs teams. Pfizer PFE has signed a definitive agreement with Arena Pharmaceuticals ARNA to acquire the latter for $100 per share or an aggregate equity value of . (SPACs), Transportation, Infrastructure & Logistics, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Access more premium companies when you subscribe to Explorer, US: Mid-size Pharma Companies (mainly specialty) by Revenue, Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics, GlobalData Plc 2022 | Registered Office: John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK | Registered in England No. Dec 14, 2021 9:10AM EST. Now he wants a divorce. In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it's done. It would be a disaster for most Americans. Akeros loss per share estimates have narrowed from $4.50 to $2.97 for 2021 and from $4.84 to $3.11 for 2022 in the past 30 days. The company also has two other yet undisclosed G proteincoupled receptor (GPCR) based therapies in early pre-clinical evaluations with collaboration agreements for development. Although patients receiving the lower, 1mg etrasimod dose also achieved each endpoint compared with placebo, results did not reach statistical significance. Arena Pharmaceuticals Media Contact: Patrick Malloy Arena Pharmaceuticals, Inc. Vice President, Investor Relations & Corporate Communications 847.987.4878 pmalloy@arenapharm.com Aristea. Published. Some better-ranked stocks from the drug/biotech sector are Bellerophon Therapeutics, Inc. BLPH, Akero Therapeutics, Inc. AKRO and Repligen Corporation RGEN, each carrying a Zacks Rank #2 (Buy). Results from the Phase III trial of Arena's etrasimod to treat ulcerative colitis are expected in the first quarter of this year. The candidate is in late-stage development as a potential treatment for active ulcerative colitis. Our Development Pipeline. Early testing on non-human subjects has shown improvement ventricular mechanical efficiency, supporting development of ADP418 for in-hospital treatments of patients with chronic heart failure. Currently, there isnt a cure for AD but treatments and self-care measures can relieve itching and help minimize new outbreaks. S&P 500 earnings estimates for 2023 take complete U-turn as recession risks loom, according to BofA. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Bellerophons loss per share estimates have narrowed from $2.75 to $2.69 for 2021 and from $2.31 to $2.27s for 2022 in the past 30 days. This release contains forward-looking information about Pfizer's proposed acquisition of Arena, Arena's pipeline portfolio, including its molecules etrasimod . MLR-US-NP-0004v1.0 05/21. Arena Pharmaceuticals APD811 Pipeline Advancement The First Of Several Upcoming Catalysts Oct. 12, 2012 3:19 PM ET Pfizer Inc. (PFE) 26 Comments Red Acre Investments 536 Follower s Shares of. In addition, Arena's pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. Currently, Arena has three primary investigational clinical programs: etrasimod, olorinab and ralinepag. Subsequently, the open-label extension study demonstrated sustained improvements in the original patients that were switched from placebo to ralinepag, with results achieving a similar magnitude of improvement. Meanwhile, the company is developing its lead pipeline candidate, etrasimod, for multiple indications. Arena Pharmaceuticals, Inc. - Product Pipeline Review - 2014 is a new market research publication announced by Reportstack. Contact Us USA 6154 Nancy Ridge Drive, San Diego, CA 92121 One Beacon Street, Floor 28 . The mortality rate remains high as DHF is a complex disease; it is also the leading cause of hospitalization for those over 65 years of age. Investors are fully responsible for any investment decisions they make. Copyright 2021 JaguarAnalytics, LLC. Arena Pharmaceuticals, Inc. ARNA announced that it has dosed the first patient in a phase II study evaluating its coronary candidate, temanogrel. Previous data from pre-clinical and clinical data support the study evaluating the use of temanogrel in patients undergoing PCI to prevent cMVO. Timber is strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. Crohns disease (CD) is a chronic inflammatory condition of the gastrointestinal tract, most commonly affecting the end of the small bowel and the beginning of the colon, but it may affect any part of the gastrointestinal tract. Our three core development programs have all received Orphan Drug status. Expansive offering allow users to identify drugs by a wide range of characteristics and features ranging from a geography, company to a specific drug. PARK CITY, Utah-- ( BUSINESS WIRE )-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind . Lorcaserin, an approved weight management drug is marketed in the United States and South Korea under license to Eisai. Many patients suffering from Crohns disease are prescribed opioids to help with pain management, however this can cause further irritation to the GI tract along with a separate issue, that of addiction to the painkiller. Our proprietary pipeline includes potentially firs . /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced a strategic shifting of priorities to emphasize its proprietary clinical stage. You are now leaving arenapharm.com and being directed to a site not maintained by Arena. In its Phase I trials, a dose-dependent reduction in total peripheral lymphocyte count was observed with estrasimod versus placebo. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. On January 24th, Arena announced closing of a license agreement with United Therapeutics (UTHR) that was entered into in late November 2018. While the rest of 2019 will be muted in terms of data releases, 2020 will likely see at least one readout, and possibly an update on ralinepag (depending on United Therapeutics timeline). Create your Watchlist to save your favorite quotes on Nasdaq.com. A mid-stage study was initiated during the last quarter to evaluate the candidate in patients with eosinophilic esophagitis. In its primary Phase II trials, ralinepag had shown a statistically significant absolute change from baseline in pulmonary vascular resistance (PVR) compared to placebo. Profiles offer detailed pharmacological and Research and Development (R&D) information affording users the market insight necessary for accurate decision making. We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Currently, Arena has three primary investigational clinical programs: etrasimod, olorinab and ralinepag. APD418 is currently in Phase 2 for acute heart failure. . Pfizer Inc.s presentation of its pending $6.7 billion acquisition of clinical-stage drug company Arena Pharmaceuticals Inc. contained no mention of cannabis. The primary endpoint of the study will be measured by the change in Index of Microcirculatory Resistance on day 1 post-PCI compared to baseline. What can I do? Why are Republicans telling voters they want to cut Social Security by a third. Proposed acquisition offers potentially new, differentiated best-in-class approach to address unmet need for a broader number of patients with immuno-inflammatory diseases. Previously, Phase II study results had shown significantly more patients achieving endoscopic improvement compared to placebo group (43.2% vs 16.3%, respectively), histological improvement (31.7% vs 10.2%), and histological remission (19.5% vs 6.1) at the 12-week point. Overall, the drug was well-tolerated in healthy test subjects. Doses of less than 1.0mg had little or no effect on T-cell counts however higher dose levels of 3.0mg and 5.0mg reduced total T-cell counts when compared to placebo group. A wealth of resources for individual investors is available at www.zacks.com. Pipeline Drugs is equipped to facilitate both qualitative and quantitative analysis. If you have questions about an Expanded Access or Compassionate Use Program, please contact. Back in March 2018, Arena completed its Phase II randomized, double-blind, placebo-controlled multinational study returning positive results after which two Phase III trials were initiated, ELEVATE UC 52 and ELEVATE UC 12, two concurrent studies that will last 52 weeks with readouts expected to be released simultaneously sometime in 2021. All rights reserved. Please note that the candidate enjoys Fast Track designation in the United States for cMVO. -0.95% Arena is currently enrolling patients. Any pipeline setback going forward will likely have an adverse impact on the companys shares. Trials have progressed to Phase III stage in which its impact on morbidity, mortality and exercise capacity is being evaluated. Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion. This study is described below. Is Cannabis Legalization The End For Pharma Stocks? Twitter founder and former chief executive, Jack Dorsey, on Saturday apologized for the layoffs involving about 50% of the staff, announced by new owner, Elon Musk on Friday. Federal cannabis legalization might reduce conventional pharmaceutical sales by billions of dollars according to a new study conducted by researchers from . Management is planning to initiate a Phase II study in AD by the end of 2019 with data sometime in 2020. Marketed Drugs seeking approval for additional indications or in additional markets are included. Among Arena Pharmaceuticals' assets is etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator with the potential to treat ulcerative colitis and a range of other conditions. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2022, Nasdaq, Inc. All Rights Reserved. Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion . . We're pursuing every opportunity to develop and bring our investigational medicines* to patients. Dec. 13 analyst call on its Arena Pharma acquisition focused primarily on etrasimod, currently in Phase 2 and 3 trials as a treatment for the chronic inflammatory bowel disease ulcerative colitis. Data from the mid-stage study is expected in the second half of 2022. As of March 31st, Arena had $1.1B in cash, including United Therapeutics payment, with over $400M in milestone payments expected in the future. Published on Sep 2, 2022. Orloinab is currently the companys leading candidate in a planned drug pipeline dedicated to cannabinoid therapeutics. Atopic dermatitis (AD), or eczema, is a condition with varying symptoms, most often manifesting as dry skin, severe itching, patches, swollen skin and raised bumps which may leak fluid. Type a symbol or company name. While enhancing performance, this treatment tends to avoid adverse events associated with current therapies. All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual's trading does not guarantee future results or returns. Shares of Arena have lost 20.8% so far this year compared with the industrys 1.1% decrease. Patients showed a 29.8% improvement in PVR compared to placebo arm and a 20.1% improvement from the baseline. Repligens earnings per share estimates increased from $2.21 to $2.26 for 2021 and from $2.53 to $2.56 for 2022 in the past 30 days. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Etrasimod is presently in late-stage development for ulcerative colitis ("UC"). In addition, Arena's pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. But it turns out that one of several medicines in the development pipeline for Arena Pharmaceuticals On February 27, Cantor Fitzgerald analyst Alethia Young reduced target price for Arena from $62. A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. Upon closing, United Therapeutics paid Arena $800 million. Keep up-to-date on new Pipeline drug developments. A fourth candidate, ADP-418, is in its pre-clinical evaluation. An internally discovered investigational drug candidate, olorinab is being explored for development in several indications as a peripherally acting (primary mechanism of action outside of the central nervous system), highly-selective, full agonist of the cannabinoid type 2 receptor (CB2): compared to CB1, CB2 does not cause psychoactive adverse effects. 03925319, Artificial Intelligence: Leading Technology Companies, Cybersecurity: Leading Technology Companies, Electric Vehicles: Leading Technology Companies, Strategic Alliances Announced in Last 12 Months, Special Purpose Acquisition Corps. Visit a quote page and your recently viewed tickers will be displayed here. The acquisition by a big pharma giant like Pfizer, which is sitting on high reserves of cash, would allow the company to advance the development of its pipeline. Arena has two key candidates etrasimod and olorinab in its pipeline. New Study Predicts Billions In Losses. But it turns out that one of several medicines in the development pipeline for Arena Pharmaceuticals ARNA is a drug to treat irritable bowel syndrome called Olorinab, or APD371, which. Its also being reviewed as a treatment for Crohns disease, irritable bowel syndrome and eosinophilic esophagitis. With no approved products, successful development of pipeline candidate is key to Arenas prospects. Arena Pharmaceuticals Inc. (Arena) is an American biopharmaceutical company founded in 1997 with a pipeline dedicated to cannabinoid-type therapeutics. RELENTLESS THINKING DOESN'T JUST DRIVE US. July 30, 2019 | 10:35 AM Olorinab is targeting pain management for two indications, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Intended to be a once-daily oral therapy targeting sphingosine-1-phosphate (S1P) receptor modulator to provide systemic and local cell modulation, etrasimod is being tried for immune and inflammatory-mediated diseases such as ulcerative colitis, Crohns disease, and atopic dermatitis, the three current indications being developed by Arena. Webinars Media Investors Careers Contact Us Pfizer and Arena Pharmaceuticals have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. From start-ups to market leaders, uncover what they do andhow they do it. Arena Pharmaceuticals, Inc. ARNA announced that it has dosed first patients in a phase II study to evaluate its key pipeline candidate etrasimod as a potential treatment for moderate-to . The acquisition was completed by way of a merger in accordance with Delaware law and, as a result of the acquisition, Arena became a wholly-owned . Zacks has released a Special Report to help you do just that, and today its free. Jaguar | avo@jaguaranalytics.com. Ulcerative colitis (UC) is a chronic disease that affects the large intestine in which the innermost lining of the large intestine becomes inflamed leading to ulcer formation on the surface causing a multitude of afflictions. The trial is expected to evaluate the effects of etrasimod, 1mg and 2mg dosage levels, versus placebo on multiple efficacy measures including a 3-component Mayo Score, total Mayo Score (TMS), clinical remission and clinical response in up to 160 patients. Arena Pharmaceuticals Pipeline News Monitoring. Earlier this week, Forbes reported that Pfizers acquisition of Arena amounts to a bet on medical cannabis and the companys entry into the pot-derived drug market. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. We're Changing the Game. Many important categories of drugs target GPCRs, which are proteins that regulate numerous aspects of human physiology. Arena currently has a Zacks Rank #3 (Hold). Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report, Repligen Corporation (RGEN): Free Stock Analysis Report, Bellerophon Therapeutics, Inc. (BLPH): Free Stock Analysis Report, Akero Therapeutics, Inc. (AKRO): Free Stock Analysis Report. Revealed in late 2018, APD418 is intended to be a first-in-class option for decompensated heart failure (DHF). ARENA Pharmaceuticals is a team with a singular purpose - deliver important medicines to patients. Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. A phase IIb/III study is evaluating etrasimod in patients with Crohn's disease. by Temanogrel is currently in Phase 2 for the treatment of microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis. Arena Pharmaceuticals (ARNA) is a San Diego-based biopharmaceutical company focused on developing small molecule drugs across a range of therapeutic areas. ARENA Pharmaceuticals is a team with a singular purpose - deliver our important medicines to patients. Written by Arena Pharmaceuticals (ARNA) is a San Diego-based biopharmaceutical company focused on developing small molecule drugs across a range of therapeutic areas. Copyright 2022 MarketWatch, Inc. All rights reserved. Its common in children but can occur at any age and is typically chronic, tending to flare periodically. dermatology and cardiology. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases . Fortunes will be made. That deal closed in May. Arena Pharmaceuticals, Inc. price | Arena Pharmaceuticals, Inc. Quote. THIS COFFEE RUN SPARKED AN IDEA TO DESIGN TRIALS WITH PATIENTS' LIVES IN MIND. Once the pipeline candidates. APD418 is currently in Phase 2 for acute heart failure. Arena> Pipeline OUR PIPELINE We're pursuing every opportunity to develop and bring our investigational medicines* to patients. IT DEFINES US. The primary endpoint is improvement in the weekly AAPS from baseline. Pipeline Drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. March 14, 2022 Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn Pfizer will gain access to Arena's portfolio of various treatment candidates for gastroenterology, dermatology and cardiology. Etrasimods selective S1P approach has the potential to improve treatment versus currently available treatment options that have limitations in terms of side effects, patient response, efficacy and administration. Pfizer has agreed to acquire Arena Pharmaceuticals for approximately $6.7 billion, the companies said today, in a deal designed to expand the buyer's immuno-inflammatory disease pipeline, led by . Pfizer would be following in the vein of Jazz Pharmaceuticals Plc All images are owned or licensed by Arena Pharmaceuticals and may not be downloaded or reproduced. At Baseline, no subject had a pain-free day, this increased to a mean of two pain-free days per week in Week 8. Arena's portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, currently in development for a. In November 2018,. About Etrasimod Etrasimod (APD334), is an oral, next generation, selective sphingosine 1-phosphate (S1P) receptor modulator, discovered by Arena, designed to provide systemic and local cell . Zacks Equity Research for About Arena Pharmaceuticals . Steve Gelsi covers banking and cannabis as a Senior Reporter for MarketWatch. in its $7.2 billion acquisition of GW Pharmaceuticals Inc., maker of Epidiolex, the first FDA-approved CBD medicine for treating types of severe epilepsy in children. When administration was discontinued, lymphocyte levels either increased back towards the baseline, or returned to original levels. Test Drive the Live Trading Chat Room: JaguarLive July 8, 2020, Conversations Trades Week Ended November 4th, JaguarConsumer Weekly Callouts November 6 (KO, ADDYY, BBWI, LOW, NKE, VSCO, SAM, MCD, DNUT, MBUU, PII, WGO). Pfizer said on Monday it would buy drug developer Arena Pharmaceuticals for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine.. Dr. Eric Gershwin is working with Arena Pharmaceuticals on a study that involves an entirely new class of drugs to treat PBC. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In FY2018, R&D plus G&A expenses were around $163M which their current bankroll can sustain for quite a long time. Decompensated heart failure is characterized by an increase in symptoms such as difficulty breathing, intolerance to exertion, swelling of the limbs, and fatigue. Gastroenterology > ETRASIMOD > The study is evaluating the safety, tolerability, and efficacy of two doses of the intravenous formulation of the candidate as a potential treatment for coronary microvascular obstruction (cMVO) in patients undergoing percutaneous coronary intervention (PCI). Moving forward trials will be conducted and reported by United Therapeutics. PFE, Do Not Sell My Personal Information (CA Residents Only). Trillions will be spent. According to finviz, the 12-month consensus target price for Arena Pharmaceuticals is $67.10. 3 not to buy: A small, cash-strapped biotech should have a focused pipeline Five years ago, Arena was working on a drug called ralinepag for pulmonary hypertension. About Arena Pharmaceuticals . The acquisition of San Diego-based Arena will bolster Pfizer's pipeline of therapeutic candidates in gastroenterology, dermatology and cardiology. Have you found what you were looking for? The company is evaluating possible strategic options for the candidate and further development of the candidate is now subject to regulatory approval. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products. See now: Cannabis stocks rally anew as $7 billion GW Pharma deal spurs interest in weed and its medical benefits. Our pipeline includes four investigational medicines in eight indications and eleven ongoing or planned clinical trials. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval. However, a mid-stage study evaluating the companys another key pipeline candidate, olorinab, in abdominal pain due to irritable bowel syndrome failed in March. During Phase II OASIS trials for ulcerative colitis, patients with eczema manifestations had responded to therapy as the S1P receptor subtypes also modulate other biological responses. Today, that discovery is still the heart of the Zacks Rank. 2000-2021 Arena Pharmaceuticals, Inc. All Rights Reserved. Pfizer is reportedly pursuing the acquisition in order to expand its scope of. Pfizer Inc said on Monday it would buy drug developer Arena Pharmaceuticals for $6.7 billion in cash, to add a promising treatment candidate that targets diseases affecting the stomach and intestine. The company is advancing the candidate to a phase III registrational program to evaluate it as a potential treatment for atopic dermatitis. NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Pfizers The dataset allows users to quickly identify specific information of value for actionable insights. Shares of Arena have lost 20.8% so far this year compared with the industry 's 1.1% decrease. The only question is Will you get into the right stocks early when their growth potential is greatest?. Ill be left with nothing. Reason No. On July 25th, Arena announced the first subject doses in CAPTIVATE Phase IIb trial for IBS, evaluating three dose levels over a twelve-week period in approximately 240 patients with various IBS-related symptoms. Pfizer Acquires Arena Pharmaceuticals To Widen Immuno-Inflammatory Disease Pipeline December 29, 2021 Premier biopharma company Pfizer has locked down a deal to acquire Arena Pharmaceuticals for $6.7 billion, an all-cash transaction that will broaden its capabilities to produce therapies for treatment of immuno-inflammation conditions such as . Temanogrel is currently in Phase 2 for the treatment of microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis. March 02, 2021 04:05 PM Eastern Standard Time. A fourth candidate, ADP-418, is in its pre-clinical evaluation. With no FDA-approved therapy for the cMVO indication, the field represents a significant opportunity for the company, if successful. In addition, all of our investigational products have significant market expansion potential into major medical dermatology . Image Source: Zacks Investment Research Meanwhile, the company is developing its lead pipeline. . ARENA Pharmaceuticals is a team with a singular purpose - deliver important medicines to patients. The company stated that 40% to 60% of patients undergoing PCI for treating acute coronary syndrome fail to achieve full myocardial reperfusion, which can lead to cMVO and increase negative cardiovascular outcomes and mortality by two to three folds. [3] The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. Mucosal healing was seen in 19.5% of patients treated with etrasimod 2mg compared to just 4.1% of placebo group. Drug giant Pfizer has inked a deal to buy Arena Pharmaceuticals in an all-cash deal valued at $6.7 billion boosting its capabilities to develop therapies targeting ulcerative colitis, Crohn's. Arena is not responsible for content or privacy policies on other sites. This report provides an overview of the Arena Pharmaceuticals, Inc.'s pharmaceutical research and development focus. Download FREE: How to Profit from Trillions on Spending for Infrastructure >>. To fuel our growth, we are unlocking the value of our . Zacks->. The deal grants United Health an exclusive global license for ralinepag and, in return, Arena received an $800M upfront compensation with up to $400M in future milestone payments as well as tiered, low double-digit royalties on net sales. Management believes they are uniquely positioned to deliver on the promise of their products with best-in-class products and a potentially high-value pipeline that has limited downside risk. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale. JAZZ, You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. ARNA stock rose more than 83% after Pfizer announced that it was acquiring Arena Pharmaceuticals at a price of $100 per share. To read this article on Zacks.com click here. Early results have shown clinical response in Average Abdominal Pain Scale (AAPS) with a 30% reduction in 85% (11/13) of all subjects with evaluable data at Week 4, and 100% (11/11) at Week 8. Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion .
Mean Of Hypergeometric Distribution, Salem Bus Stand Phone Number, Bucked Up Woke Af Ingredients, Henry Stop Leak Vs Flex Seal, Noble Medical Vaughan, One-class Image Classification Github, Who Were The Republicans In The Spanish Civil War,
